Compare · LLY vs PRQR
LLY vs PRQR
Side-by-side comparison of Eli Lilly and Company (LLY) and ProQR Therapeutics N.V. (PRQR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PRQR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.13T, about 4640.4x PRQR ($242.7M).
- Over the past year, LLY is up 48.0% and PRQR is down 23.4% - LLY leads by 71.4 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 7 for PRQR).
- LLY has more recent analyst coverage (25 ratings vs 18 for PRQR).
- Company
- Eli Lilly and Company
- ProQR Therapeutics N.V.
- Price
- $1196.14+0.89%
- $1.72-3.91%
- Market cap
- $1.13T
- $242.7M
- 1M return
- +7.05%
- -4.97%
- 1Y return
- +48.02%
- -23.39%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 11
- 7
- Recent ratings
- 25
- 18
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Latest LLY
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,000 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,905 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,410 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,734 units (SEC Form 4)
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Latest PRQR
- Amendment: SEC Form SCHEDULE 13G/A filed by ProQR Therapeutics N.V.
- Director Filius Bart bought $257,925 worth of Ordinary Shares (150,000 units at $1.72), increasing direct ownership by 100% to 300,000 units (SEC Form 4)
- SEC Form EFFECT filed by ProQR Therapeutics N.V.
- SEC Form 424B5 filed by ProQR Therapeutics N.V.
- Chief Executive Officer De Boer Daniel Anton bought $261,000 worth of Ordinary Shares (150,000 units at $1.74), increasing direct ownership by 100% to 300,000 units (SEC Form 4)
- Chief Executive Officer De Boer Daniel Anton bought $238,500 worth of Ordinary Shares (150,000 units at $1.59) (SEC Form 4)
- SEC Form F-3 filed by ProQR Therapeutics N.V.
- Amendment: SEC Form 4 filed by Director Hinsch Gylvin Lykke
- Director Filius Bart bought $231,000 worth of Ordinary Shares (150,000 units at $1.54) (SEC Form 4)
- SEC Form 6-K filed by ProQR Therapeutics N.V.